Fast recovery with etanercept in patients affected by polymyalgia rheumatica and decompensated diabetes: a case-series study

Risultato della ricerca: Article

8 Citazioni (Scopus)

Abstract

We enrolled nine consecutive patients affected by newly diagnosed polymyalgia rheumatica and decompensated diabetes mellitus. All patients were treated with etanercept (25 mg twice weekly) and prednisone and were followed up to 1 year. At the sixth-month follow-up, etanercept and prednisone were withdrawn. Patients were seen at regular intervals (days 0, 30, 60, 90, 150, 180) and the following variables determined: erythrocytes sedimentation rate, C-reactive protein, fasting serum glucose, pain measured by visual analog scale, and the Health Assessment Questionnaire. Our results indicate that etanercept might have some steroid-sparing effects, but controlled investigations are needed to support etanercept use in clinical practice for this kind of patients.
Lingua originaleEnglish
pagine (da-a)89-92
Numero di pagine4
RivistaClinical Rheumatology
Volume28
Stato di pubblicazionePublished - 2009

Fingerprint

Polymyalgia Rheumatica
Prednisone
Blood Sedimentation
Pain Measurement
C-Reactive Protein
Fasting
Diabetes Mellitus
Steroids
Glucose
Etanercept
Health
Serum

All Science Journal Classification (ASJC) codes

  • Rheumatology

Cita questo

@article{a4c24aa63d2f45499a0a6882930a5d3b,
title = "Fast recovery with etanercept in patients affected by polymyalgia rheumatica and decompensated diabetes: a case-series study",
abstract = "We enrolled nine consecutive patients affected by newly diagnosed polymyalgia rheumatica and decompensated diabetes mellitus. All patients were treated with etanercept (25 mg twice weekly) and prednisone and were followed up to 1 year. At the sixth-month follow-up, etanercept and prednisone were withdrawn. Patients were seen at regular intervals (days 0, 30, 60, 90, 150, 180) and the following variables determined: erythrocytes sedimentation rate, C-reactive protein, fasting serum glucose, pain measured by visual analog scale, and the Health Assessment Questionnaire. Our results indicate that etanercept might have some steroid-sparing effects, but controlled investigations are needed to support etanercept use in clinical practice for this kind of patients.",
keywords = "Biological therapy; Decompensated diabetes mellitus; Etanercept; Polymyalgia rheumatica; Steroid therapy",
author = "Giuseppe Licata and Rosario Scaglione and Daniela Colomba and Luigi Calvo and Giovanni Pistone",
year = "2009",
language = "English",
volume = "28",
pages = "89--92",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",

}

TY - JOUR

T1 - Fast recovery with etanercept in patients affected by polymyalgia rheumatica and decompensated diabetes: a case-series study

AU - Licata, Giuseppe

AU - Scaglione, Rosario

AU - Colomba, Daniela

AU - Calvo, Luigi

AU - Pistone, Giovanni

PY - 2009

Y1 - 2009

N2 - We enrolled nine consecutive patients affected by newly diagnosed polymyalgia rheumatica and decompensated diabetes mellitus. All patients were treated with etanercept (25 mg twice weekly) and prednisone and were followed up to 1 year. At the sixth-month follow-up, etanercept and prednisone were withdrawn. Patients were seen at regular intervals (days 0, 30, 60, 90, 150, 180) and the following variables determined: erythrocytes sedimentation rate, C-reactive protein, fasting serum glucose, pain measured by visual analog scale, and the Health Assessment Questionnaire. Our results indicate that etanercept might have some steroid-sparing effects, but controlled investigations are needed to support etanercept use in clinical practice for this kind of patients.

AB - We enrolled nine consecutive patients affected by newly diagnosed polymyalgia rheumatica and decompensated diabetes mellitus. All patients were treated with etanercept (25 mg twice weekly) and prednisone and were followed up to 1 year. At the sixth-month follow-up, etanercept and prednisone were withdrawn. Patients were seen at regular intervals (days 0, 30, 60, 90, 150, 180) and the following variables determined: erythrocytes sedimentation rate, C-reactive protein, fasting serum glucose, pain measured by visual analog scale, and the Health Assessment Questionnaire. Our results indicate that etanercept might have some steroid-sparing effects, but controlled investigations are needed to support etanercept use in clinical practice for this kind of patients.

KW - Biological therapy; Decompensated diabetes mellitus; Etanercept; Polymyalgia rheumatica; Steroid therapy

UR - http://hdl.handle.net/10447/121165

M3 - Article

VL - 28

SP - 89

EP - 92

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

ER -